SCHEMBL7144781

SCHEMBL7144781

COc1cccc(NS(=O)(=O)CSc2nc3ccccc3s2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
LMNA P02545 6/20 0.52
ALDH1A1 P00352 6/20 0.52
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
HTT P42858 2/20 0.52
TP53 P04637 4/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
KDM4E B2RXH2 1/20 0.47
GLO1 Q04760 1/20 0.47
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
THRB P10828 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149256 0.92 MAPT (0.54) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7151736 0.90 ALDH1A1 (0.56) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7151080 0.89 LMNA (0.49) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7154367 0.88 L3MBTL1 (0.55) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7149836 0.88 ALDH1A1 (0.51) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7155045 0.87 ALDH1A1 (0.50) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7154107 0.86 MAPT (0.52) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7149774 0.85 MAPT (0.50) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7151274 0.81 PDK1 (0.55) MAPTLMNAALDH1A1RAB9ANPC1
SCHEMBL7154990 0.81 ALDH1A1 (0.49) MAPTLMNAALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 MAPT 3839/4885LMNA 1481/4885ALDH1A1 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.